

Seyed Mehdi Sadat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1311708/publications.pdf>

Version: 2024-02-01

29
papers

545
citations

840119

11
h-index

642321

23
g-index

30
all docs

30
docs citations

30
times ranked

922
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymeric nanoparticles. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 321-332.	1.4	219
2	HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 641-649.	1.0	36
3	Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2012, 20, 53.	0.9	30
4	Application of Outer Membrane Vesicle of <i>Neisseria meningitidis</i> Serogroup B as a New Adjuvant to Induce Strongly Th1-Oriented Responses Against HIV-1. <i>Current HIV Research</i> , 2011, 9, 630-635.	0.2	27
5	Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. <i>Journal of Materials Science: Materials in Medicine</i> , 2015, 26, 179.	1.7	26
6	Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. <i>Immunology Letters</i> , 2015, 168, 366-373.	1.1	26
7	Updated Studies on the Development of HIV Therapeutic Vaccine. <i>Current HIV Research</i> , 2019, 17, 75-84.	0.2	21
8	Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19. <i>Molecular Biotechnology</i> , 2021, 63, 389-409.	1.3	17
9	Frequency and Genotype of Hepatitis D Virus Infection in Patients Infected with HIV and Those Undergoing Hemodialysis. <i>Hepatitis Monthly</i> , 2013, 13, e7481.	0.1	14
10	Application of SCR Priming VLP Boosting as a Novel Vaccination Strategy Against HIV-1. <i>Current HIV Research</i> , 2011, 9, 140-147.	0.2	13
11	Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles. <i>Current Drug Delivery</i> , 2020, 17, 387-395.	0.8	12
12	Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine. <i>Jundishapur Journal of Microbiology</i> , 2016, 9, e33909.	0.2	11
13	Genotyping of human parechoviruses in Iranian young children with aseptic meningitis and sepsis-like illness. <i>Journal of NeuroVirology</i> , 2013, 19, 595-600.	1.0	9
14	Design, synthesis and anti-HIV-1 evaluation of a series of 5-hydroxypyridine-4-one derivatives as possible integrase inhibitors. <i>Medicinal Chemistry Research</i> , 2015, 24, 4113-4127.	1.1	9
15	Outer membrane vesicle of <i>Neisseria meningitidis</i> serogroup B as an adjuvant to induce specific antibody response against the lipopolysaccharide of <i>Brucella abortus</i> S99. <i>Annals of Microbiology</i> , 2009, 59, 145-149.	1.1	8
16	Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer. <i>Hepatitis Monthly</i> , 2013, 13, e14178.	0.1	8
17	Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. <i>IUBMB Life</i> , 2019, 71, 1645-1652.	1.5	7
18	Delivery of HIV-1 Polyepitope Constructs Using Cationic and Amphipathic Cell Penetrating Peptides into Mammalian Cells. <i>Current HIV Research</i> , 2020, 17, 408-428.	0.2	7

#	ARTICLE	IF	CITATIONS
19	Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients with Specific Medical Conditions. PLoS ONE, 2015, 10, e0139171.	1.1	6
20	Docking studies of some 5-hydroxypyridine-4-one derivatives: evaluation of integrase and ribonuclease H domain of reverse transcriptase as possible targets for anti-HIV-1 activity. Medicinal Chemistry Research, 2015, 24, 2195-2212.	1.1	6
21	HIV-1 p24-nef DNA Vaccine plus Protein Boost Expands T-Cell Responses in BALB/c. Current Drug Delivery, 2021, 18, .	0.8	6
22	Impact of null genotypes of GSTT1 and GSTM1 with uterine leiomyoma risk in Iranian population. Journal of Obstetrics and Gynaecology Research, 2016, 42, 434-439.	0.6	5
23	Measurement of opsonophagocytic activity of antibodies specific to <i>Neisseria meningitidis</i> serogroup A capsular polysaccharide-serogroup B outer membrane vesicle conjugate in animal model. Annals of Microbiology, 2009, 59, 801-806.	1.1	4
24	Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination. Medical Oncology, 2011, 28, 660-666.	1.2	4
25	Biological and Immunological Evaluation of <i>Neisseria meningitidis</i> Serogroup A Outer Membrane Vesicle as Vaccine Candidates. Jundishapur Journal of Microbiology, 2013, 6, .	0.2	4
26	Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations. Medicinal Chemistry, 2013, 9, 526-538.	0.7	3
27	Effective Delivery of Nef-MPER-V3 Fusion Protein Using LDP12 Cell Penetrating Peptide for Development of Preventive/Therapeutic HIV-1 Vaccine. Protein and Peptide Letters, 2020, 27, 1151-1158.	0.4	3
28	Introducing a frameshift mutation to the Pol sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3). Molecular Biology, 2012, 46, 467-472.	0.4	2
29	Production and Evaluation of the Properties of HIV-1-Nef-MPER-V3 Fusion Protein Harboring IMT-P8 Cell Penetrating Peptide. Current HIV Research, 2020, 18, 315-323.	0.2	2